Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

InMed Pharmaceuticals (INM) Other Accumulated Expenses (2022 - 2023)

InMed Pharmaceuticals (INM) has 2 years of Other Accumulated Expenses data on record, last reported at $2.3 million in Q1 2023.

  • For Q1 2023, Other Accumulated Expenses changed N/A year-over-year to $2.3 million; the TTM value through Mar 2023 reached $2.3 million, changed N/A, while the annual FY2022 figure was $3.2 million, N/A changed from the prior year.
  • Other Accumulated Expenses reached $2.3 million in Q1 2023 per INM's latest filing, down from $2.4 million in the prior quarter.
  • Across five years, Other Accumulated Expenses topped out at $3.3 million in Q3 2022 and bottomed at $2.3 million in Q1 2023.